Evidence map›Paper›PMID 38830870›Full record

ArticleCell death & disease2024

O-GlcNAcylation controls pro-fibrotic transcriptional regulatory signaling in myofibroblasts.

Ninon Very, Clémence Boulet, Céline Gheeraert, Alexandre Berthier, Manuel Johanns, Mohamed Bou Saleh, Loïc Guille, Fabrice Bray, Jean-Marc Strub, Marie Bobowski-Gerard and 12 more

Abstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Ninon VeryUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.ORCID 0000-0003-4250-5819
Clémence BouletUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Céline GheeraertUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Alexandre BerthierUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Manuel JohannsUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Mohamed Bou SalehUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Loïc GuilleUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.ORCID 0000-0002-8387-1092
Fabrice BrayMiniaturization for Synthesis, Analysis & Proteomics, UAR 3290, CNRS, University of Lille, Villeneuve d'Ascq Cedex, France.
Jean-Marc StrubLaboratoire de Spectrométrie de Masse BioOrganique, CNRS UMR7178, Univ. Strasbourg, IPHC, Infrastructure Nationale de Protéomique ProFI - FR2048, Strasbourg, France.ORCID 0000-0001-6224-3428
Marie Bobowski-GerardUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.ORCID 0000-0002-0915-0799
Francesco P ZummoUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.ORCID 0000-0001-5923-1784
Emmanuelle VallezUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Olivier Molendi-CosteUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.ORCID 0000-0002-0498-9456
Eloise WoitrainUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Sarah CianféraniLaboratoire de Spectrométrie de Masse BioOrganique, CNRS UMR7178, Univ. Strasbourg, IPHC, Infrastructure Nationale de Protéomique ProFI - FR2048, Strasbourg, France.
David MontaigneUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Line Carolle Ntandja-WandjiUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Laurent DubuquoyUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.ORCID 0000-0003-3596-5497
Julie Dubois-ChevalierUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Bart StaelsUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.ORCID 0000-0002-3784-1503
Philippe LefebvreUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Jérôme EeckhouteUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France. jerome.eeckhoute@inserm.fr.ORCID 0000-0002-7222-9264

Funding

Agence Nationale de la Recherche (French National Research Agency) ANR-10-INBS-08-03Agence Nationale de la Recherche (French National Research Agency) ANR 10 LABX-0046Agence Nationale de la Recherche (French National Research Agency) ANR-16-IDEX-0004 ULNEAgence Nationale de la Recherche (French National Research Agency) ANR-16-RHUS-0006-PreciNASHAgence Nationale de la Recherche (French National Research Agency) ANR 21 CE17-0016-02
6 · The paper itself

Abstract

Tissue injury causes activation of mesenchymal lineage cells into wound-repairing myofibroblasts (MFs), whose uncontrolled activity ultimately leads to fibrosis. Although this process is triggered by deep metabolic and transcriptional reprogramming, functional links between these two key events are not yet understood. Here, we report that the metabolic sensor post-translational modification O-linked β-D-N-acetylglucosaminylation (O-GlcNAcylation) is increased and required for myofibroblastic activation. Inhibition of protein O-GlcNAcylation impairs archetypal myofibloblast cellular activities including extracellular matrix gene expression and collagen secretion/deposition as defined in vitro and using ex vivo and in vivo murine liver injury models. Mechanistically, a multi-omics approach combining proteomic, epigenomic, and transcriptomic data mining revealed that O-GlcNAcylation controls the MF transcriptional program by targeting the transcription factors Basonuclin 2 (BNC2) and TEA domain transcription factor 4 (TEAD4) together with the Yes-associated protein 1 (YAP1) co-activator. Indeed, inhibition of protein O-GlcNAcylation impedes their stability leading to decreased functionality of the BNC2/TEAD4/YAP1 complex towards promoting activation of the MF transcriptional regulatory landscape. We found that this involves O-GlcNAcylation of BNC2 at Thr

Indexed as

MyofibroblastsSignal TransductionAcetylglucosamineAdaptor Proteins, Signal TransducingAnimalsFibrosisHumansMaleMiceMice, Inbred C57BLProtein Processing, Post-TranslationalTEA Domain Transcription FactorsTranscription FactorsTranscription, GeneticYAP-Signaling ProteinsAcetylglucosamineAdaptor Proteins, Signal TransducingTEA Domain Transcription FactorsTranscription FactorsYAP-Signaling Proteins

Identifiers

PMID38830870
PMCPMC11148087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.